ATNM — Stock Film
STOCK FILMSCENE 1/11ATNM · $1.12
Stock Expert AI presents
ATNM
Actinium Pharmaceuticals, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Actinium Pharmaceuticals, Inc. A quick introduction.

It operates in the world of health and science. It has 25 employees. Now — the numbers.

25 employees
$32.6M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $378.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 47% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$1.1M
2021
$1M
2022
$81K
2023
$0
2024
$90K
2025
In the vault right now:
$0
DEBT: $1.7M
At this pace, that money lasts about 1.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
94
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
82
very strong

A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.

VALUATION
67
strong

Clearly above the class average — a step short of the very top.

GROWTH
60
average

There is growth, but not at top-of-the-class tempo.

PRICE MOMENTUM
34
very weak

Clearly below the class average.

WORTH WATCHING

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
Costs eat into the margin4/10
WORTH WATCHING

Cost Efficiency: As sales grow, profit fails to keep the same pace.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Sales are holding up

The company sells $90K a year; the problem isn’t sales — it’s costs running above that number.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $11.07888% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $33.9M against $90K in annual sales.

2
THE RISKS · 2/3
The cash has a countdown

At the current pace of spending, the cash lasts about 1.4 years. After that, the company needs to find new money.

3
THE RISKS · 3/3
Executives lean toward selling

Over the last 12 months, executives reported 49 sells against just 7 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ATNM sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ATNM is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film